ROCKVILLE, Md., Aug. 12, 2020 /PRNewswire/ — Emmes today announced that it provided the data and statistical analysis support for the Phase 1 clinical trial of the investigational COVID-19 vaccine mRNA-1273. Three Emmes employees were co-authors on the Preliminary Report about the clinical trial, “An mRNA Vaccine against SARS-CoV-2,” published in the New England Journal of Medicine on July 14.
{iframe}https://www.biospace.com/article/releases/emmes-announces-its-role-in-phase-1-covid-19-vaccine-trial/{/iframe}